TrialBMC endocrine disorders2017

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.

Seung-Hwan Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.